🔗 Share this article

As the United States undertakes historic revisions to its immunization schedules, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has zeroed in on potential fatalities following Covid vaccination in her brief time at the FDA.

Proposed Changes to Childhood Immunization Schedule

Public health authorities had intended to announce radical revisions to the pediatric vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a major change that would put the US at odds with a large portion of the international standard with no evidence for improved outcomes. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to run the division this year.

A Shift at the Agency

This interim role might represent a strengthened alliance between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for halting specific pediatric shot schedules in the US to become more like the Danish model, a nation with universal health coverage and a citizenry roughly the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – usually the purview of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Qualifications

Dr. Høeg has no obvious track record in medication creation, approval processes or leadership, which has been standard for previous heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Previous directors of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who headed CBER have had.”

CDER has an enormous range of responsibilities at the agency, she emphasized.

“The public just focuses on the new drug program, but the generic program approves thousands of generic medications. There is also a biosimilars program, OTC medication office and other areas, and all of those must be managed,” Dr. Woodcock noted. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial management aspect to the role, which oversees more than 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” she added.

Agency Reaction and Controversial Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among regulatory chiefs on immunizations, a representative said that the “inquiries rely on incorrect premises”.

“Her experience aligns with the duties of her position,” the official said, pointing to the period Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's new expedited review system, a controversial expedited therapy clearance system that reportedly worried her preceding directors. “By what process are these drugs being chosen for this expedited pathway? Who makes the choices?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards less stringent regulations of pharmaceuticals, aside from vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if troubling, history, critics said. She authored a analysis using unconfirmed public submissions to determine the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are more dangerous than they are.

Included in her “desired changes” for the incoming government included altering guidelines for novel immunizations and halting “optional” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has allegedly proposed barring teenage boys from obtaining COVID-19 vaccines.

“She’s an complete ideologue who commences with her conclusions and reverse-engineers to fit the data in a very deceptive, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|